Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Anything goes -- Ignore unavailable to you. Want to Upgrade?

To: Brett Fleischman who wrote (20774)	5/22/1998 11:40:00 AM
From: cool	Respond to of 34592

ORVX--7 M float--some DD-- OraVax, Inc. Joins DynPort In Department of Defense Contract To Develop FDA-Licensed Vaccines Against Potential Biological Warfare Agents CAMBRIDGE, Mass., May 04 /PRNewswire/ -- OraVax, Inc. (Nasdaq: ORVX - news) announced today its participation in a defense contract awarded to DynPort L.L.C., as Prime Systems Integration Contractor. The contract is for the Joint Vaccine Acquisition Program (JVAP) of the U.S. Department of Defense (DoD). DynPort's proposal was chosen from four bids offered to the Department of Defense's public Request for Proposals. OraVax is working with DynPort and the JVAP office to refine plans for the advanced development and routine manufacture of selected vaccines under this contract. Several vaccines are anticipated to be manufactured by OraVax at its Canton, Massachusetts production facility. The Joint Vaccine Acquisition Program is a $322 million, 10-year program for the development, production, testing, FDA licensure and storage of vaccines to protect U.S. armed forces against potential biological warfare agents. The JVAP is implemented by the DoD through the Joint Program Office for Biological Defense, for which the U.S. Army is the lead agency. This program was developed to ensure that the military will have access to a supply of FDA-approved vaccines effective against potential biological warfare agents. The vaccines under the JVAP will be subject to the same scrutiny and rigorous examination the FDA applies to vaccine products for civilian use. ''Recent current events show just how vital it is to be prepared to protect against the threat of biologic warfare,'' said Lance K. Gordon, Ph.D., President and Chief Executive Officer of OraVax. ''We are very pleased to have the opportunity to manufacture a series of vaccines that are important for national defense. Once approved by the FDA, these products could also be made more broadly available to counter the consequences of biologic warfare.'' Dr. Gordon also added, ''Performance under this contract should provide a long-term, stable business unit to the Company that should extend our manufacturing operations and facilitate OraVax's own proprietary product manufacture.'' DynPort, as prime contractor, and OraVax, as manufacturer for specified products, will receive the existing investigational vaccines from the Department of Defense and will work with product managers at the JVAP office to further establish the safety and efficacy required for licensure by the FDA. OraVax is a Cambridge, Massachusetts biopharmaceutical company engaged in the discovery and development of innovative vaccines and antibody products to prevent or treat human infectious diseases. The Company's largest program, Helicobacter pylori (H. pylori), is a joint venture with Pasteur Merieux Connaught to develop vaccines against peptic ulcers and stomach cancer. OraVax is also developing HNK20, a monoclonal IgA antibody nosedrop for prevention of infant viral pneumonia caused by respiratory syncytial virus (RSV), and both a vaccine and a stimulated-immune globulin for the prevention of colitis caused by Clostridium difficile, a common complication of broad- spectrum antibiotic therapy. Additionally, the Company is developing the ChimeriVax(TM) family of single-dose genetically-engineered vaccines based on the yellow fever YF 17D vaccine strain virus. The first of these vaccines, targeting the Japanese encephalitis virus, is currently in advanced preclinical development. Earlier stage research programs include vaccines against dengue, tick borne encephalitis and hepatitis C viral infections.

To: Brett Fleischman who wrote (20774)	5/22/1998 11:40:00 AM
From: Wayne Rumball	Read Replies (1) \| Respond to of 34592

MIDL- It is not a question of whether the stuff works or not, it does. Question is will EXXON try to buy the stuff or the patent. MIDL will make money either way when their plant begins production. In any case the warrents are still in the money There are 332 million gallons of gasoline sold daily in the U.S. Arcon will receive 5.4 cents per gallon cash rebate from the federal government on all ethanol gasoline blended and sold by Arcon containing DF-144. A prominent international refining consultant retained by Arcon has estimated the demand for DF-144 would be in excess of 70 plants to cover the northern and southern parts of California. Until now, ethanol-based gasoline has not been sold in the state. Each DF-144 plant at 100,000 gallons per day will produce $36 million per annum and net $7 million, and production commences in September 1998. - DF-144 is not ether-based and is therefore more environmentally ''friendly'' than additives such as MTBE or ETBE. A bill introduced by Senator Feinstein would require other states to drop MTBE from gasoline (see MTBE on the Internet) and replace it with ethanol.